Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study
- DOI
- 10.1016/j.jtct.2026.06.034
- Published
- 2026-06
- Container
- Transplantation and Cellular Therapy
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtct.2026.06.034,
title = {Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study},
author = {Carl Shultz and Shreyas Shirodkar and Chelby Wakefield and Steven Rollins and Sijin Wen and Kelly Ross and Michael Craig and Aaron Cumpston and Mehdi Hamadani and Abraham S. Kanate and Lauren Veltri},
year = {2026},
journal = {Transplantation and Cellular Therapy},
doi = {10.1016/j.jtct.2026.06.034},
url = {https://doi.org/10.1016/j.jtct.2026.06.034}
}RIS
TY - JOUR TI - Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study AU - Carl Shultz AU - Shreyas Shirodkar AU - Chelby Wakefield AU - Steven Rollins AU - Sijin Wen AU - Kelly Ross AU - Michael Craig AU - Aaron Cumpston AU - Mehdi Hamadani AU - Abraham S. Kanate AU - Lauren Veltri PY - 2026 JO - Transplantation and Cellular Therapy DO - 10.1016/j.jtct.2026.06.034 UR - https://doi.org/10.1016/j.jtct.2026.06.034 ER -
APA
Shultz, C., Shirodkar, S., Wakefield, C., Rollins, S., Wen, S., Ross, K., Craig, M., Cumpston, A., Hamadani, M., Kanate, A. S., & Veltri, L. (2026). Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2026.06.034
Source records
- crossref · retrieved 2026-09-25T15:07:49.391Z